Research
Cost-effectiveness of pioglitazone in type 2 diabetes patients with a history of macrovascular disease: a German perspective
-
* Corresponding author: William J Valentine valentine@ossianconsulting.com
1 Universität Düsseldorf, Klinik für Endokrinologie, Diabetologie und Rheumatologie
2 IMS Health, Basel, Switzerland
3 University of Perugia, Medicine and Metabolic Diseases, Perugia, Italy
4 Medizinische Klinik III der Universität zu Köln, Köln, Germany
Cost Effectiveness and Resource Allocation 2009, 7:9 doi:10.1186/1478-7547-7-9
Published: 5 May 2009Additional files
Additional file 1:
Summary of events and event rates from the PROactive study. The table presents the annual hazard rates observed over months 0–36 of the PROactive study and incorporated into the model.
Format: DOC Size: 62KB Download file
This file can be viewed with: Microsoft Word Viewer
Additional file 2:
Disutility values used in the base case and sensitivity analyses. The table presents the quality of life utility values used within the model.
Format: DOC Size: 56KB Download file
This file can be viewed with: Microsoft Word Viewer
Additional file 3:
Summary of sensitivity analysis results for pioglitazone versus placebo. The table presents the summary results of all sensitivity analyses performed in the cost-effectiveness evaluation of pioglitazone versus placebo.
Format: DOC Size: 64KB Download file
This file can be viewed with: Microsoft Word Viewer